Vasoactive intestinal polypeptide appears to be one of the mediators in misoprostol-enhanced small intestinal transit in rats.

Chang FY, Doong ML, Chen TS, Lee SD, Wang PS

Journal of gastroenterology and hepatology1 Oct 2000Cited by 10 (Europe PMC)

PMID11106090DOI10.1046/j.1440-1746.2000.02306.xPepBankPUB-11106090

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, oral misoprostol at doses above 10 microg/kg lowered plasma VIP levels.
In plain wordsIn rats, higher oral doses of misoprostol lowered the body's own VIP in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePlasma VIP after higher oral misoprostol doses
Study
ratn: not reported in source
Rats given misoprostol
Comparator
Lower misoprostol doses
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
Neither charcoal evaluated transit nor the plasma VIP level was influenced by the lower doses of oral misoprostol treatment (1 and 10 microg/kg), whereas other doses enhanced SIT and diminished the plasma VIP level (P< 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effect of misoprostol on rat SIT and looked at the role of vasoactive intestinal polypeptide (VIP) release during its action.
Summary · context
The plasma VIP level was measured by using a radioimmunoassay kit.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1110609001
02AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, oral misoprostol at 1 and 10 microg/kg did not change plasma VIP levels.
In plain wordsIn rats, the two lowest oral doses of misoprostol did not change the body's own VIP in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePlasma VIP after lower oral misoprostol doses
Study
ratn: not reported in source
Rats given misoprostol
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
Neither charcoal evaluated transit nor the plasma VIP level was influenced by the lower doses of oral misoprostol treatment (1 and 10 microg/kg)
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effect of misoprostol on rat SIT and looked at the role of vasoactive intestinal polypeptide (VIP) release during its action.
Summary · context
The plasma VIP level was measured by using a radioimmunoassay kit.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1110609002
03AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, intraperitoneal misoprostol gave similar effects on plasma VIP levels as oral misoprostol, with lower VIP.
In plain wordsIn rats, misoprostol by injection also lowered the body's own VIP in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePlasma VIP after intraperitoneal misoprostol
Study
ratn: not reported in source
Rats given misoprostol
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
The similar effects on radiochromium computed SIT (P< 0.01) and plasma VIP levels were obtained in tubed rats following misoprostol intraperitoneal treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effect of misoprostol on rat SIT and looked at the role of vasoactive intestinal polypeptide (VIP) release during its action.
Summary · context
The plasma VIP level was measured by using a radioimmunoassay kit.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1110609003
04AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats, small intestinal transit results correlated negatively with plasma VIP levels.
In plain wordsIn rats, faster gut transit went with lower body's own VIP levels in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCorrelation of transit with plasma VIP
Study
ratn: not reported in source
Rats given misoprostol
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
The SIT results correlated negatively with plasma VIP levels.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effect of misoprostol on rat SIT and looked at the role of vasoactive intestinal polypeptide (VIP) release during its action.
Summary · context
The plasma VIP level was measured by using a radioimmunoassay kit.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-1110609004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.